Listed

Arbutus Biopharma Corp: Form 10-Q for the period ended Mar 31, 2015

Filed with the SEC on May 6, 2015 and accepted by EDGAR at May 6, 2015, 17:25 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2015-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2015-01-01 to 2015-03-31$4.7mus-gaap:Revenues
Research and development3 months2015-01-01 to 2015-03-31$10.6mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2015-01-01 to 2015-03-31−$18.0mus-gaap:OperatingIncomeLoss
Net income3 months2015-01-01 to 2015-03-31−$12.0mus-gaap:NetIncomeLoss
Basic EPS3 months2015-01-01 to 2015-03-31−$0.40us-gaap:EarningsPerShareBasic
Operating cash flow3 months2015-01-01 to 2015-03-31−$17.8mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2015-01-01 to 2015-03-31$141.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2015-03-31$232.3mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2015-03-31$239.8mus-gaap:AssetsCurrent
Total assetsAt period end2015-03-31$787.1mus-gaap:Assets
Current liabilitiesAt period end2015-03-31$24.9mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2015-03-31$193.4mus-gaap:Liabilities
Shareholders' equityAt period end2015-03-31$593.7mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001171843-15-002592. Last ingested by Listed: Nov 12, 2026, 17:55 ET. Listed shows no prices and gives no investment advice.